Market Indices
Sector Heatmap
CUE — Cue Biopharma, Inc.
NasdaqCue Biopharma, Inc.
- O
- 25.60
- H
- 25.92
- L
- 24.67
- V
- 156.83K
CUE — Latest News & Headlines
20 Stories$CUE stock is down 28% today. Here's what we see in our data. - Quiver Quantitative
$CUE stock is down 28% today. Here's what we see in our data. Quiver Quantitative
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results - Yahoo Finance
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results Yahoo Finance
Why is Cue Biopharma stock surging today? - Investing.com
Why is Cue Biopharma stock surging today? Investing.com
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win For CSU With Novel Dual MOA - Seeking Alpha
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win For CSU With Novel Dual MOA Seeking Alpha
Understanding the Setup: (CUE) and Scalable Risk - Stock Traders Daily
Understanding the Setup: (CUE) and Scalable Risk Stock Traders Daily
Cue Biopharma (CUE) Retreats 7.07% to $25.51, Sitting at the Midpoint of Its Recent Range - Wide Range Bar - siam.in
Cue Biopharma (CUE) Retreats 7.07% to $25.51, Sitting at the Midpoint of Its Recent Range - Wide Range Bar siam.in
AAPL Stock Hits Record Highs — Apple Reportedly Explores Screenless Health Trackers And Other Wearables Following iPhone Duo Launch - TradingView
AAPL Stock Hits Record Highs — Apple Reportedly Explores Screenless Health Trackers And Other Wearables Following iPhone Duo Launch TradingView
GOOGL, AMZN, SNDK Stocks Hit 52-Week Highs Today: What's Fueling The Rally? - Stocktwits
GOOGL, AMZN, SNDK Stocks Hit 52-Week Highs Today: What's Fueling The Rally? Stocktwits
Seoul stocks open higher on chip gains - The Korea Herald
Seoul stocks open higher on chip gains The Korea Herald
B.Riley reiterates Cue Biopharma stock rating on allergy data By Investing.com - Investing.com Nigeria
B.Riley reiterates Cue Biopharma stock rating on allergy data By Investing.com Investing.com Nigeria
Top Premarket Gainers - Yahoo Finance
Top Premarket Gainers Yahoo Finance
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset - Seeking Alpha
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset Seeking Alpha
Seoul stocks open higher on chip gains - The Korea Herald
Seoul stocks open higher on chip gains The Korea Herald
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response - Yahoo Finance
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response Yahoo Finance
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CUE) 2026-09-24 - Seeking Alpha
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CUE) 2026-09-24 Seeking Alpha
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart? - Yahoo Finance
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart? Yahoo Finance
Act Now: Micron Could Skyrocket After Sept. 30 - Yahoo Finance
Act Now: Micron Could Skyrocket After Sept. 30 Yahoo Finance
Cue Biopharma stock swings after positive CUE-221 Phase 2 data and profit-taking - ad-hoc-news.de
Cue Biopharma stock swings after positive CUE-221 Phase 2 data and profit-taking ad-hoc-news.de
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket - benzinga.com
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket benzinga.com
Biotech stocks and leveraged ETFs lead market d... - Pluang
Biotech stocks and leveraged ETFs lead market d... Pluang